Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ziconotide.

Katherine A Lyseng-Williamson1, Caroline Perry

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|April 8, 2006
PubMed
Summary

Ziconotide, an intrathecal analgesic, effectively manages chronic pain by blocking N-type calcium channels. Clinical trials show significant pain relief compared to placebo, with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3.

Contemporary clinical trials communications·2025
Same author

Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.

Lancet (London, England)·2025
Same author

US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary-Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab.

Journal of digestive diseases·2024

Area of Science:

  • Pharmacology
  • Neurology
  • Pain Management

Background:

  • Chronic intractable pain affects millions globally, necessitating effective analgesic strategies.
  • Current treatments often have limitations or side effects, driving the search for novel therapies.
  • Ziconotide offers a targeted approach to pain management via intrathecal administration.

Purpose of the Study:

  • To evaluate the efficacy and safety of ziconotide for chronic intractable pain.
  • To assess ziconotide's impact on pain intensity and opioid use.
  • To determine the long-term efficacy and tolerability of ziconotide treatment.

Main Methods:

  • Three pivotal, randomized, placebo-controlled trials of 5-6 or 21 days' duration.
  • Assessment of pain intensity using Visual Analogue Scale (VAS) scores.
  • Evaluation of secondary endpoints including patient response rates and changes in opioid consumption.

Main Results:

  • Ziconotide demonstrated statistically significant improvements in VAS pain intensity scores compared to placebo.
  • Secondary endpoints, such as pain relief and reduced opioid use, supported ziconotide's efficacy.
  • Preliminary long-term data (up to 12 months) indicate sustained analgesic effect.
  • Most adverse events were mild-to-moderate, neurological, and reversible upon discontinuation.

Conclusions:

  • Ziconotide is an effective intrathecal analgesic for chronic intractable pain.
  • Gradual titration and low initial doses minimize adverse events.
  • Ziconotide offers a valuable therapeutic option with a favorable safety profile, including no reported respiratory depression.

Related Experiment Videos